Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution
29. Oktober 2024 08:00 ET
|
Grifols, S.A.
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management...
Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
22. Oktober 2024 08:00 ET
|
Grifols, S.A.
Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare agent ...
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
29. Juli 2024 08:00 ET
|
Grifols, S.A.
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy ...
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
01. Juli 2024 06:00 ET
|
Grifols, S.A.
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as...
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
18. Juni 2024 07:30 ET
|
Grifols, S.A.
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a...
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
17. Juni 2024 04:20 ET
|
Grifols, S.A.
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing...
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
18. April 2024 09:30 ET
|
Grifols, S.A.
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The...
Procleix ArboPlex Assay® da Grifols recebe a marca CE, o primeiro e único NAT 4 em 1 para o rastreio de arbovírus
04. April 2024 04:00 ET
|
Grifols, S.A.
O teste de ácido nucleico in vitro da Grifols deteta quatro tipos de arbovírus, ajudando a reduzir o risco de infeções transmitidas por transfusãoOs arbovírus são uma ameaça emergente crescente, com...
Procleix ArboPlex Assay® di Grifols, primo e unico test NAT 4-in-1 per lo screening degli arbovirus, riceve il marchio CE
04. April 2024 04:00 ET
|
Grifols, S.A.
Il test NAT in vitro di Grifols rileva quattro tipi di arbovirus, contribuendo a ridurre il rischio di infezioni trasmesse tramite trasfusioneGli arbovirus sono una minaccia emergente in crescita,...
Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren
04. April 2024 04:00 ET
|
Grifols, S.A.
Der In-vitro-Nukleinsäuretest von Grifols weist vier Arten von Arboviren nach und trägt dazu bei, das Risiko transfusionsbedingter Infektionen zu verringernArboviren stellen eine wachsende Bedrohung...